Coadministration of Dabigatran Etexilate and Atorvastatin
- PDF / 230,910 Bytes
- 10 Pages / 612.28 x 790.86 pts Page_size
- 77 Downloads / 174 Views
ORIGINAL RESEARCH ARTICLE
ª 2009 Adis Data Information BV. All rights reserved.
Coadministration of Dabigatran Etexilate and Atorvastatin Assessment of Potential Impact on Pharmacokinetics and Pharmacodynamics Joachim Stangier,1 Karin Rathgen,1 Hildegard Sta¨hle,1 Kathrin Reseski,2 Thomas Ko¨rnicke2 and Willy Roth1 1 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany 2 PAREXEL International GmbH, Berlin, Germany
Abstract
Background: Dabigatran etexilate, a novel oral direct thrombin inhibitor, has been approved for prophylaxis of thromboembolism in patients undergoing total knee or total hip replacement, and is under clinical investigation for treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation, and the treatment of thromboembolic complications following acute coronary syndromes. Objective: To evaluate the potential impact of atorvastatin coadministration on the pharmacokinetics, pharmacodynamics, and safety of dabigatran etexilate. Methods: Healthy male and female volunteers (n = 22) were recruited to this open, randomized, multipledose, three-way crossover study. They received dabigatran etexilate 150 mg twice daily on days 1–3 and once daily on day 4, atorvastatin 80 mg once daily on days 1–4, or both treatments together on days 1–4. Results: Exposure to dabigatran at steady state (area under the drug plasma concentration-time curve at steady state) was reduced by 18% with concomitant atorvastatin administration. An 18% increase in plasma atorvastatin concentration occurred with coadministration of dabigatran etexilate. Exposure to its metabolite 20 -hydroxy-atorvastatin remained essentially unchanged and exposure to 40 -hydroxy-atorvastatin was increased by 15%. The small changes observed are deemed of little clinical relevance given the overall interindividual variability in the metabolism of atorvastatin. Furthermore, there were no changes in the concentrations of active HMG-CoA reductase inhibitors in plasma following dabigatran etexilate coadministration. Six subjects in the atorvastatin treatment group, six subjects during combination treatment, and eight subjects in the dabigatran treatment group reported adverse events. Most of the adverse events reported were nervous system disorders such as dizziness and headache, and general disorders such as fatigue. All adverse events were resolved at the end of the study. Conclusion: Results of this randomized, open-label, three-way crossover design study in healthy male and female volunteers showed that atorvastatin had no influence on the pharmacokinetic/pharmacodynamic profile of dabigatran, and vice versa, dabigatran etexilate had no impact on the pharmacokinetic/pharmacodynamic profile of atorvastatin. Both drugs were well tolerated when given alone or in combination.
Background Anticoagulants are used for the prevention and treatment of thromboembolic events in a wide variety of indications. These include the treatment and prevention of venous thromboembolic events – deep vein thrombosis an
Data Loading...
